<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00424840</url>
  </required_header>
  <id_info>
    <org_study_id>UM200601</org_study_id>
    <nct_id>NCT00424840</nct_id>
  </id_info>
  <brief_title>Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy</brief_title>
  <official_title>Phase I/II Study to Evaluate the Efficacy and Safety of Combination Chemotherapy With Carboplatin, Bortezomib and Bevacizumab as First Line Therapy in Patients With Advanced Non-small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Massachusetts, Worcester</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Millennium Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Genentech, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Massachusetts, Worcester</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pilot trial of combination of bortezomib, bevacizumab and carboplatin as first line therapy
      in patients with metastatic Non-Small Cell Lung Cancer (NSCLC). Phase I and II study of this
      combination in first line setting will be conducted in order to properly estimate the
      efficacy and safety of this regimen. This will form the basis for future studies comparing
      this combination to what is now considered standard regimen for first line therapy in
      patients with NSCLC, carboplatin, paclitaxel and bevacizumab.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study design and methodology The study will have two phases.

      The phase I will use traditional dose escalation model (3-6 patient per dose level) to
      determine the maximum tolerated dose (MTD).

      *[In phase II, either level III or (MTD) will be used in the same every 21 day cycle to
      evaluate the efficacy and safety of the regimen in first line treatment of advanced NSCLC]*
      not conducted.

      Treatments administered

      In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed
      dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose
      (MTD).

      A maximum of six cycles will be administered. Patients with complete response, partial
      response or stable disease after six cycles will be allowed to continue on single agent
      bevacizumab every 3 weeks as maintenance therapy until disease progression.

      If no dose limiting toxicity (DLT) is observed in 3 patients during the first cycle, the next
      dose level will be accrued. If 1 DLT is observed, 3 additional patients will be accrued to
      the dose level. If no additional DLTs are observed, the next dose level will be accrued.
      However, if 2 or more DLTs are observed in a given dose level, MTD will be defined. MTD will
      be defined as the dose below which ≥2 DLTs were observed.

      The following three levels will be studied:

      Level I (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.3
      mg/m2 D8 : bortezomib 1.3 mg/m2

      Level II (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.6
      mg/m2 D8 : bortezomib 1.6 mg/m2

      Level III(every 21 day cycle):D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1.8
      mg/m2 D8 : bortezomib 1.8 mg/m2

      If 2 or more DLT are observed in Level 1, level -1 will be accrued.

      Level -1: (every 21 day cycle): D1: carboplatin AUC 6, bevacizumab 15 mg/kg, bortezomib 1
      mg/m2 D8: bortezomib 1 mg/m2

      *[In phase II, either level III or the MTD dose level will be used in the same every 21 day
      cycle to evaluate the efficacy and safety of the regimen in first line treatment of advanced
      NSCLC.

      Efficacy data collected

      The following evaluations will be conducted to assess the efficacy of the combination:

        -  response rate by Response Evaluation Criteria in Solid Tumors (RECIST) criteria

        -  disease free and overall survival, time to progress (TTP) and duration of response
           Safety data collected

      The following evaluations will be conducted to assess the safety of the combination
      chemotherapy:

      • toxicity based on National Cancer Institute-Common Terminology Criteria for Adverse Events
      (NCI-CTCAE) version 3.0]* Not conducted

      Statistical procedures

      In phase I portion, 9-18 patients will be enrolled. The patients treated at recommended dose
      level for phase II will also be eligible for response evaluation as part of phase II.

      *[The primary objective of the phase II study is to estimate the efficacy and safety of the
      combination therapy with carboplatin, bortezomib and bevacizumab as the first line therapy in
      patients with advanced NSCLC. The primary endpoints are response rate and progression-free
      survival (PFS).

      (NOT CONDUCTED) In phase II portion, the optimal two-stage design for phase II clinical
      trials described by Simon et al. will be utilized.

      Overall survival, progression free survival and time to progression will be estimated using
      Kaplan-Meier methods. Time to progression, progression free survival and survival will be
      calculated from the date of study entry.]* (Phase II not conducted.)
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor accrual
  </why_stopped>
  <start_date>June 2006</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</measure>
    <time_frame>up to 21 days for each dosing cycle</time_frame>
    <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 1 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 2 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Level 3 of Bortezomib Dose Escalation in combination with Carboplatin AUC6, Bevacizumab 15 mg/kg and Taxotere 70 + G-CSF</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.3 mg/m2</intervention_name>
    <description>Level I (every 21 day cycle, D8), 1.3 mg/m2:
Day 1: bevacizumab 15 mg/kg ,carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.3 mg/m2 Day 8 : bortezomib 1.3 mg/m2
Level II (every 21 day cycle):
Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.6 mg/m2 Day 8 : bortezomib 1.6 mg/m2
Level III(every 21 day cycle):
Day 1: bevacizumab 15 mg/kg, carboplatin Area Under the Curve (AUC 6) 900mg, bortezomib 1.8 mg/m2 Day 8 : bortezomib 1.8 mg/m2</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.6 mg/m2</intervention_name>
    <description>Level II (every 21 day cycle, D8), 1.6 mg/m2</description>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bortezomib 1.8 mg/m2</intervention_name>
    <description>Level III (every 21 day cycle, D8) 1.8 mg/m2</description>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <other_name>Velcade</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 6</intervention_name>
    <description>Carboplatin AUC6</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
    <other_name>Carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab 15 mg/kg</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxotere</intervention_name>
    <description>Taxotere 70 + G-CSF</description>
    <arm_group_label>Bortezomib 1.3 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.6 mg/m2</arm_group_label>
    <arm_group_label>Bortezomib 1.8 mg/m2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed SCLC (adeno- and large cell, anaplastic carcinoma and
             broncho-alveolar-carcinoma). Patients with squamous-cell histology are eligible with
             extra thoracic or peripheral lung lesions only.

          -  Sputum cytology alone not acceptable evidence of cell type. Cytologic specimens
             obtained by brushing, washings, or needle aspiration of defined lesions will be
             acceptable. Mixed tumors will be categorized by the predominant cell type unless a
             small cell anaplastic elements are present, in which case the patient is ineligible.

          -  Stage III B because of pleural effusion or Stage IV disease

          -  Measurable disease.

          -  Age: 18 years or older

          -  No history of thrombotic, hemorrhagic, or coagulopathy disorders

          -  international normalized ratio (INR&lt;1.5) and a prothrombin time (PTT) no greater than
             normal limits of normal within 1 week prior to registration. NB: subjects with lung
             cancer placed on anticoagulant therapy for a thrombotic event are not eligible for
             this study.

          -  No gross hemoptysis (defined as bright red blood of ½ teaspoon or more)

          -  No central nervous system (CNS) or brain metastasis

          -  Laboratory Criteria (completed &lt;2 weeks before enrollment):

               -  Hematologic: white blood cell (WBC) &gt; 3500/mm3 or absolute neutrophil count (ANC)
                  &gt; 1500/mm3 and platelet count &gt; 100 000/ mm3;

               -  Hepatic: Total bilirubin &lt; 1.5 mg/dl

               -  Renal: Creatinine &lt; 1.5 mg/dl. or calculated

               -  Creatinine clearance &gt; 45 ml/min (NB: Urine protein:creatinine ratio in exclusion
                  criteria)

          -  Eastern Cooperative Oncology Group (ECOG) performance status &lt; 2

          -  Be free of active infection.

          -  Be available for active follow up.

          -  No prior chemotherapy for metastatic disease.

          -  Be disease free for &gt; 5 years if they had a prior second malignancy other than treated
             basal cell carcinoma or squamous cell skin cancer, or carcinoma in situ of the cervix.

          -  Female subject post-menopausal; surgically sterilized or willing to use an acceptable
             method of birth control for the duration of the study. Male subject agrees to use an
             acceptable method for contraception for the duration of the study.

        Exclusion Criteria:

          -  CNS or brain metastasis

          -  Patient has = or greater Grade 2 peripheral neuropathy within 14 days before
             enrollment.

          -  Known previous sensitivity reactions with boron, or mannitol,

          -  Patients with known HIV positivity

          -  Myocardial infarction within 6 months prior to enrollment or has New York Hospital
             Association (NYHA) Class III or IV heart failure, uncontrolled angina, severe
             uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute
             ischemia or active conduction system abnormalities. Any ECG abnormality at Screening
             has to be documented by the investigator as not medically relevant.

          -  Blood pressure of &gt;150/100 mmHG

          -  History of myocardial infarction or stroke within 6 months

          -  Clinically significant peripheral vascular disease

          -  Major surgical procedure, open biopsy, or significant traumatic injury within 28 days
             prior to Day 0, anticipation of need for major surgical procedure during the course of
             the study.

          -  Minor surgical procedure such as fine needle aspirations or core biopsies within 7
             days prior to day 0

          -  Urine protein: Creatinine ratio &gt; 1.0 at screening

          -  History of abdominal fistula, gastrointestinal perforation, or intraabdominal abscess
             within 6 months prior to Day 0

          -  Serious, non-healing wound, ulcer, or bone fracture

          -  Lung carcinoma or any histology in close proximity to a major vessel or cavitation

          -  Female subject is pregnant or breast-feeding. Confirmation that the subject is not
             pregnant. Pregnancy testing is not required for post-menopausal or surgically
             sterilized women.

          -  Patient has received other investigational drugs with 14 days before enrollment or is
             expected to participate in an experiment drug study during this study treatment.

          -  Serious medical or psychiatric illness likely to interfere with participation in this
             clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>William Walsh, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of MassachusettsMedical School</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655-0002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials. 1989 Mar;10(1):1-10.</citation>
    <PMID>2702835</PMID>
  </reference>
  <reference>
    <citation>Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006 Dec 14;355(24):2542-50. Erratum in: N Engl J Med. 2007 Jan 18;356(3):318.</citation>
    <PMID>17167137</PMID>
  </reference>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>January 18, 2007</study_first_submitted>
  <study_first_submitted_qc>January 19, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2007</study_first_posted>
  <results_first_submitted>June 17, 2016</results_first_submitted>
  <results_first_submitted_qc>January 30, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>January 30, 2019</last_update_submitted>
  <last_update_submitted_qc>January 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Massachusetts, Worcester</investigator_affiliation>
    <investigator_full_name>William Walsh</investigator_full_name>
    <investigator_title>Study Principle Investigator</investigator_title>
  </responsible_party>
  <keyword>lung cancer, Carboplatin, bortezomib, Bevacizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Bortezomib</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Treatment q21 day cycle, maximum of 6 cycles. Patients with CR, PR, SD continued on single agent bevacizumab 15 mb/kg q 3 weeks.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Dose Level 1: 1.3 mg/m^2 Bortezomib</title>
          <description>Level 1 participants were given 1.3 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
        <group group_id="P2">
          <title>Dose Level II: 1.6 mg/m^2</title>
          <description>Participants were given1.6 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
        <group group_id="P3">
          <title>Dose Level III: 1.8 mg/m^2</title>
          <description>1.8 mg/m^2 Bortezomib with Carboplatin AUC6, bevacizumab 15 mg/kg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Phase I: Dose Level 1, 2 and 3</title>
          <description>1.3 mg/m^2 Bortezomib&quot;, &quot;1.6 mg/m^2 Bortezomib&quot;, and &quot;1.8 mg/m^2 Bortezomib
In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose (MTD).</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" lower_limit="49" upper_limit="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</title>
        <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
        <time_frame>up to 21 days for each dosing cycle</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Phase I: Dose Level 1</title>
            <description>1.3 mg/m^2 Bortezomib</description>
          </group>
          <group group_id="O2">
            <title>Phase 1 Dose Level II:</title>
            <description>1.6 mg/m^2 Bortezomib</description>
          </group>
          <group group_id="O3">
            <title>Phase I Dose Level III</title>
            <description>1.8 mg/m^2 Bortezomib</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Subjects Who Require Dose Delay/Reduction in Dose of Bortezomibin the First Cycle</title>
          <description>Dose limiting toxicity at Level 1,2 and 3: Number of subjects who required dose delay/reduction in dose of bortezomib in the first cycle of treatment. DLT defined by any of the following during first cycle: (1) GR4 neutropenia or thrombocytopenia, (2) Greater than GR3 non-hematological toxicity except alopecia or inadequately treated nausea or vomiting or (3) neurosensory toxicity of GR2 with pain or any neurotoxicity greater than GR2.</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 years</time_frame>
      <desc>From date of first dose to date of death or up to 2 years, whichever came first Adverse event data by separate arms not available</desc>
      <group_list>
        <group group_id="E1">
          <title>Phase I: Bevacizumab, Carboplatin, Bortezomib</title>
          <description>In phase I, three dose levels of weekly bortezomib will be studied in conjunction with fixed dose carboplatin and bevacizumab on a 21 day cycle to define the maximum tolerated dose (MTD).
Bevacizumab will be administered first followed by carboplatin followed by bortezomib</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Peripheral Neuropathy</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was closed prematurely because of poor accrual prior to initiation of Phase 2, and is underpowered to definitely estimated the response rate and progression free survival.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. William Walsh</name_or_title>
      <organization>University of Massachusetts Medical School</organization>
      <phone>508-334-5539</phone>
      <email>William.Walsh@umassmemorial.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

